Who Owns Piramal Pharma Solutions?

• Parent Company: Piramal Pharma Limited
• Ownership Type: Wholly owned
• Company Type: Publicly Traded
• Stock Ticker: NSE: PPLPHARMA

• Founded: 2007
• Founders: Piramal Pharma (internal development)

• Founded: 1988
• Headquarters: Mumbai, India
• Company Type: Publicly Traded
• Stock: NSE: PPLPHARMA
• Revenue: approximately INR 82 billion (FY2024)
• Employees: Approximately 10,000

Visit Piramal Pharma Limited website

• Headquarters: Mumbai, India
• Manufacturing / Operations: India, United States, United Kingdom, Europe

Piramal Pharma Solutions operates under Piramal Pharma Limited's comprehensive sustainability framework, which emphasizes environmental stewardship, social responsibility, and ethical business practices across its global CDMO operations. The company has embedded sustainability into its core business strategy, moving beyond basic Environmental, Social and Governance (ESG) compliance to create measurable impact across its contract development and manufacturing services.

Environmental Sustainability: Piramal Pharma Solutions maintains state-of-the-art manufacturing facilities across India, the United States, United Kingdom, and Europe that comply with stringent environmental regulations and sustainability standards. The company focuses on responsible manufacturing practices, waste reduction, energy efficiency, and sustainable resource management across its production sites. As part of Piramal Pharma's commitment to environmental stewardship, the division participates in corporate-wide initiatives to minimize environmental impact while maintaining high-quality pharmaceutical production standards.

Quality Excellence and Regulatory Compliance: The division maintains rigorous quality standards across all its facilities, successfully clearing inspections by regulatory authorities including the US FDA, UK MHRA, and other global regulators. Piramal Pharma Solutions' commitment to quality is woven into the fabric of the organization, with quality being viewed as a collective responsibility. This dedication to excellence ensures that all contract development and manufacturing services meet the highest industry standards and regulatory requirements.

Corporate Social Responsibility: Piramal Pharma Solutions collaborates with the Piramal Foundation and various partner organizations to support community development and social welfare initiatives. The division maintains its commitment to corporate social responsibility alongside Piramal Group, actively participating in community engagement programs and environmental care initiatives. This commitment extends beyond regulatory compliance to include meaningful contributions to community development and social welfare.

Ethical Business Practices: With a globally diverse workforce serving pharmaceutical companies across multiple continents, Piramal Pharma Solutions maintains strong ethical standards and corporate governance practices. The company's stakeholder-centric approach ensures that business decisions consider the interests of clients, employees, communities, and shareholders. This ethical framework guides the company's operations across its global footprint in over 100 countries.

Customer Satisfaction and Stakeholder Centricity: In 2025, Piramal Pharma Solutions achieved an impressive Net Promoter Score (NPS) of 55, far surpassing industry averages. This accomplishment, validated by third-party provider DNV, reflects the organization's dedication to stakeholder centricity and operational excellence. The high NPS score demonstrates the company's commitment to building strong, trust-based relationships with its clients and delivering exceptional service quality.

Sustainable Growth Strategy: Piramal Pharma Solutions is focused on achieving sustainable and profitable growth for all stakeholders while providing comprehensive CDMO services to pharmaceutical companies globally. The division's expansion strategy includes facility upgrades and new construction projects, such as the multipurpose state-of-the-art Antibody-Drug Conjugate (ADC) manufacturing facility in Grangemouth, Scotland, maintaining its commitment to quality, compliance, and sustainable business practices throughout its growth trajectory.

Piramal Pharma Solutions has achieved significant recognition both for its excellence in contract development and manufacturing services and its commitment to customer satisfaction and sustainability. The division's awards and acknowledgments reflect its position as a leading global CDMO and its dedication to operational excellence, innovation, and stakeholder value.

Customer Satisfaction Excellence: In 2025, Piramal Pharma Solutions achieved an impressive Net Promoter Score (NPS) of 55, far surpassing industry averages and demonstrating exceptional customer satisfaction. This accomplishment, validated by third-party provider DNV, reflects the organization's dedication to stakeholder centricity and operational excellence. The high NPS score is particularly notable in the competitive CDMO industry where customer relationships and service quality are critical differentiators.

CDMO Leadership Awards 2024: Piramal Pharma Solutions was recognized as a winner in 4 categories across Overall, Small and Big Pharma segments at the prestigious CDMO Leadership Awards 2024. This multi-category recognition demonstrates the company's broad excellence across different market segments and its ability to serve diverse pharmaceutical company needs effectively.

CMO Leadership Awards 2022: The division continued its award success by winning in 6 categories across Small Pharma segments at the CMO Leadership Awards 2022. This consistent recognition across multiple years highlights Piramal Pharma Solutions' sustained excellence and leadership position in the contract manufacturing industry.

BioSpectrum Excellence Awards: Piramal Pharma Solutions was named "Top Indian Bioservices Company of the Year" for two consecutive years (2020-21 and 2021-22) at the BioSpectrum Excellence Awards. This back-to-back recognition demonstrates the company's dominant position in the Indian bioservices sector and its consistent performance excellence.

Global CDMO Customer Value Leadership Award: In 2021, Piramal Pharma Solutions received the Frost & Sullivan 2021 Best Practices Award for Global CDMO Customer Value Leadership. This award recognizes the company's ability to deliver exceptional value to customers through innovative solutions, operational excellence, and strategic partnerships.

Industry Partner Recognition: The company was awarded "Industry Partner of the Year 2018" at the Global Generics & Biosimilars Awards during the CPhI Conference. This recognition highlights Piramal Pharma Solutions' reputation as a trusted and valuable partner in the pharmaceutical industry.

Customer Experience Excellence: Piramal Pharma Solutions received the "Best Customer Experience Award of the Year - Pharmaceutical" at Customer Fest 2016, demonstrating its early commitment to customer-centric service delivery, which has continued to evolve and strengthen over subsequent years.

Manufacturing and Technology Excellence: The company's ongoing facility expansions and technology investments, including the state-of-the-art ADC manufacturing facility in Grangemouth, Scotland, represent recognition of its technical capabilities and commitment to advancing pharmaceutical manufacturing technologies.

Piramal Pharma Solutions has maintained a strong operational record throughout its history as a leading global CDMO, with no major product recalls, regulatory violations, or significant controversies documented in public sources. The company's focus on quality excellence, regulatory compliance, and customer relationships has helped it avoid the types of issues that commonly affect pharmaceutical manufacturing companies operating in highly regulated global markets.

Quality and Compliance Track Record: Throughout its 15+ years of operation, Piramal Pharma Solutions has maintained an excellent track record of regulatory compliance across its global facilities. The company's manufacturing sites in India, the United States, United Kingdom, and Europe have successfully cleared inspections by multiple regulatory authorities, including the US FDA, UK MHRA, and other global regulators. This consistent compliance record reflects the company's investment in quality systems, manufacturing excellence, and regulatory expertise.

No Major Product Recalls: As a contract development and manufacturing organization serving pharmaceutical companies, Piramal Pharma Solutions has not experienced any major product recalls that would indicate systemic quality issues. The company's focus on quality as a collective responsibility, woven into the fabric of the organization, has contributed to its ability to maintain high standards across all manufacturing processes and client projects.

Limited Public Controversies: Unlike some pharmaceutical companies that have faced significant public controversies related to pricing, marketing practices, or ethical issues, Piramal Pharma Solutions has maintained a low public profile with minimal controversies. The company's business-to-business focus on serving pharmaceutical companies rather than direct consumer markets, combined with its emphasis on quality and compliance, has helped it avoid the types of public scrutiny that affect more consumer-facing pharmaceutical companies.

Customer Relationship Management: Piramal Pharma Solutions' exceptional Net Promoter Score of 55 in 2025, validated by third-party provider DNV, demonstrates the strength of its customer relationships and the absence of significant client disputes or controversies. This high customer satisfaction score reflects the company's ability to maintain positive, trust-based relationships with its pharmaceutical industry clients.

Regulatory Environment Navigation: Operating manufacturing facilities across multiple continents requires navigating complex regulatory environments, and Piramal Pharma Solutions has successfully managed these challenges without major compliance failures. The company's experience with multiple regulatory authorities and its established quality systems have enabled it to maintain compliance across diverse international markets.

Ethical Business Practices: The company's commitment to ethical business practices and corporate governance has helped it avoid the types of ethical controversies that can affect pharmaceutical companies. Piramal Pharma Solutions' stakeholder-centric approach ensures that business decisions consider the interests of all stakeholders, contributing to transparent and ethical operations.

Industry Reputation: Piramal Pharma Solutions has built a strong reputation in the CDMO industry, as evidenced by its multiple awards and recognitions, including the CDMO Leadership Awards and BioSpectrum Excellence Awards. This positive industry reputation reflects the company's ability to operate without significant controversies while maintaining high standards of service and quality.

Operational Excellence: The company's focus on operational excellence and continuous improvement has contributed to its ability to avoid operational issues that could lead to controversies. Piramal Pharma Solutions' investment in technology, facilities, and talent demonstrates its commitment to maintaining high operational standards.